(Q47981308)

7 February 2018

review article

1 reference

title

Colony-stimulating factors in the prevention of solid tumors induced by chemotherapy in patients with febrile neutropenia (English)

1 reference

7 February 2018

1 reference

Freyer G

1

1 reference

7 February 2018

Ligneau B

series ordinal

2

1 reference

7 February 2018

Trillet-Lenoir V

series ordinal

3

1 reference

7 February 2018

publication date

1 April 1998

1 reference

7 February 2018

International Journal of Antimicrobial Agents

published in

1 reference

7 February 2018

volume

10

1 reference

7 February 2018

issue

1

1 reference

7 February 2018

page(s)

3-9

1 reference

7 February 2018

Selective decontamination of the digestive tract and its role in antimicrobial prophylaxis

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900016-8

7 January 2021

Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900016-8

7 January 2021

A prospective evaluation of the activity of human granulocyte-colony stimulating factor on the prevention of chemotherapy-related neutropenia in patients with advanced carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900016-8

7 January 2021

Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) as Adjunct Therapy in Relapsed Hodgkin Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900016-8

7 January 2021

Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900016-8

7 January 2021

Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900016-8

7 January 2021

Recombinant granulocyte colony stimulating factor in the treatment of small cell lung cancer: a long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900016-8

7 January 2021

Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900016-8

7 January 2021

Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900016-8

7 January 2021

Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900016-8

7 January 2021

Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900016-8

7 January 2021

Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900016-8

7 January 2021

American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900016-8

7 January 2021

Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900016-8

7 January 2021

LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900016-8

7 January 2021

A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900016-8

7 January 2021

Dosing regimen of granulocyte-macrophage colony-stimulating factor to support dose-intensive chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900016-8

7 January 2021

Efficacy and tolerability of recombinant human granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related leukopenia and fever

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900016-8

7 January 2021

Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900016-8

7 January 2021

Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900016-8

7 January 2021

Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900016-8

7 January 2021

Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2898%2900016-8

7 January 2021

10.1016/S0924-8579(98)00016-8

Identifiers

DOI

1 reference

7 February 2018

1 reference

7 February 2018